Demant A/S (OTCMKTS:WILYY) vs. Bone Biologics (NASDAQ:BBLG) Critical Comparison

Bone Biologics (NASDAQ:BBLG) and Demant A/S (OTCMKTS:WILYY) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Volatility and Risk

Bone Biologics has a beta of 0.31, indicating that its share price is 69% less volatile than the S&P 500. Comparatively, Demant A/S has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500.

Institutional and Insider Ownership

34.3% of Bone Biologics shares are held by institutional investors. 13.0% of Bone Biologics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Bone Biologics and Demant A/S’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bone Biologics	N/A	N/A	-$8.95 million	N/A	N/A
Demant A/S	$3.26 billion	2.39	$260.63 million	N/A	N/A

Demant A/S has higher revenue and earnings than Bone Biologics.

Profitability

This table compares Bone Biologics and Demant A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bone Biologics	N/A	-151.99%	-121.03%
Demant A/S	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent recommendations for Bone Biologics and Demant A/S, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bone Biologics	0	0	0	0	N/A
Demant A/S	0	0	2	0	3.00

Summary

Demant A/S beats Bone Biologics on 6 of the 8 factors compared between the two stocks.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

About Demant A/S

Demant A/S operates as a hearing healthcare and audio technology company in Europe, North America, the Asia Pacific, Asia, and internationally. It operates through two segments: Hearing Healthcare and Communications. The Hearing Healthcare segment is involved in the manufacturing, servicing, and sale of hearing aids, and diagnostic products and services. The Communications segment provides headsets and solutions for the professional call centers, office markets, and gaming markets under the EPOS brand name. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Smørum, Denmark.